Utopia Capital Research

Capital research

[Utopia Capital Research @UtopiaCap]

Disclaimer: Utopia Capital holds a short position in $TROO. This content is for informational purposes only and does not constitute investment advice.

TROO is being marketed as a fintech growth story, but public records, filings, and trading behavior raise serious concerns about transparency, governance, and shareholder risk.

Recent price action is driven primarily by social media hype and retail speculation, not fundamentals. Sharp volume spikes, extreme volatility, and narrative-driven promotion are consistent with pump-style dynamics, not institutional accumulation or real operating demand.

The company claims exposure to insurance, APIs, blockchain, and software, but disclosures suggest a closed-loop structure, where capital appears to recycle internally through related entities rather than generate real shareholder value.

TROO has changed names multiple times. In micro-cap markets, repeated rebranding often signals attempts to reset investor perception and distance current narratives from prior performance, increasing downside risk once momentum fades.

Key red flags include:

$52M Hong Kong court judgment tied to alleged fraudulent transfers

Winding-up proceedings against subsidiaries

Unexplained cash outflows following reported balances

Circular buy–sell–buyback transactions with shell or delisted entities

Investments into entities with no operations or financial disclosures

Auditor turnover and governance concerns

These patterns raise serious concerns around related-party activity, insider alignment, and information asymmetry. While no wrongdoing is alleged, these are classic indicators of governance failure and elevated investor risk.

Importantly, the borrow fee is approximately 3% annually. Even in the event of an extended SEC trading halt, the economic impact remains limited. For example, a six-month halt would imply roughly a 1.5% borrow cost, during which capital may be temporarily tied up. Once trading resumes, stocks with these characteristics historically reprice sharply lower.

Based on valuation gaps, legal exposure, structural opacity, and historical precedent, we believe that upon unhalting, the stock could be down as much as 90%, with a meaningful risk of delisting.

Downside materially outweighs any upside. Sell the stock.
Utopia Capital out.

[Utopia Capital Research @UtopiaCap]

Disclaimer: Utopia Capital holds a short position in $NBY. This is for informational purposes only and does not constitute investment advice. NovaBay Pharmaceuticals — $NBY — is being misread as a turnaround. It’s not, It’s a publicly traded shell with concentrated control, no operating business, and a structure that historically ends one way. Here are the facts. NovaBay sold its only meaningful asset, Avenova, for approximately $15.6 million. That sale eliminated the company’s only revenue-generating product. Shortly thereafter, operations were wound down, employees were laid off, and the company disclosed it does not expect meaningful future revenue, No products, No pipeline, No operating business. Then came the distraction. NovaBay issued a $0.80 per share cash dividend, distributing more than $8 million — the majority of the asset sale proceeds. That wasn’t value creation. It was liquidation. Cash out, shell left behind. Next, control changed hands.Not through common stock purchases — but through preferred shares with super-voting rights. For a relatively small capital outlay, effective voting control was secured. Common shareholders retained exposure — but lost influence. This is the critical point. A company with: No business No revenue visibility And centralized voting control no longer an operating biotech. It is a corporate vehicle. And corporate vehicles tend to be used. Historically, structures like this are followed by a large equity issuances a scenario that results in material dilution for common shareholders. Fair Value & Timing With the stock trading around $10 , and approximately 126 million shares outstanding and 6 million float, we believe a more realistic valuation for a controlled public shell is between $0.40 and $0.60 per share — representing approximately 90% to 95% downside from current levels. In our view, this repricing can occur over the coming months, particularly as: Cash balances decline Corporate actions are announced Liquidity fades There is no catalyst required. The outcome is structural. This isn’t about optimism or pessimism. It’s about incentives and control. Do your own research and sell the stock. Utopia Capital out.

[BMF Reports @BmfReports]

We Are Short $TROO

After a forensic review of SEC filings, Hong Kong court records, and TROO’s so-called “investments,” we believe this is a closed-loop shell trading on optics — not cash, not operations, not reality.

We see 80–90% downside as this story unravels.

FULL REPORT: https://t.co/TLXncWyy0v

[BMF Reports @BmfReports]

$MAGH trading has been suspended.

[maninapurpledress @maninapurpledr1]

@BmfReports I believe $magh has knowingly and willfully lied to the SEC and that the company and its advisors will be sued by the government and other parties.

[Utopia Capital Research @UtopiaCap]

@BmfReports perfect. email sent.

[Utopia Capital Research @UtopiaCap]

Disclaimer: Utopia Capital holds a short position in $MAGH. This is for informational purposes only and does not constitute investment advice. Magnitude International – OTC: $MAGH. A Singapore 'construction' shell that's up 300% in a month on pure hype. This $208 million mirage trades at $5.935 today, backed by 35 million shares – but zero fundamentals. Underwriter Bancroft Capital, tied to SEC-suspended social media scams like Premium Catering (PC), enables the playbook. No earnings, no contracts – just November's volume bomb: 3 million shares a day, 100x normal, from Telegram pumps, WhatsApp blasts, and fake orders by company promoters. Insiders? Dumping 8.8 million shares. Our call: 90% drop to $0.50 in weeks. SEC, halt this now. @SECGov, investigate! Timeline: SPAC debut August 12 at $3.80, craters 70% to $1.19 by mid-month. Dormant at $1.30 on 50K volume – classic accumulation. November? No trigger, but +315% to $5.935 on spoofed spikes. August-Oct: 150K avg volume, post-IPO dump. Early Nov: Sideways trap at 30K shares. Mid-Nov pump: +240% on 1.8 million volume, Late Nov: +26% extension on 1.5 million, but Dec 2 volume? Just 196K – down 94%. Orchestrated, not organic. Bancroft Capital: Serial enabler in IPO kills. Pumps 200-500%, then 90% wipes – billions lost. SEC nailed PC for manipulation via social hype, underwritten by Bancroft alums. MAGH? Mirror: Company promoters flood Whatsapp/Telegram/Reddit with 'must-buys' – zero diligence. Spoofing exposed – fake bids baiting retail. Paid promos buried in filings. Insiders flooding 25% of float. Pattern: Closed-group bots, spoof, flip to FOMO retail, ghost.Fundamentals? Negative P/E, flat revenue, ballooning debt – vague Singapore promises. Pump fakeout. No news, OTC wild west. Trades 10x book on dust. Thesis: Volume's dead – expect 8.8 million share tsunami, spoof bids gone, SEC halt. Target: $0.50 by year-end. Upside? Only if you're short.Retail: Sell yesterday. Regulators: Probe Bancroft's web. This isn't investing – it's theft. Repost, tag the SEC, and short the scams. Utopia Capital out.

[maninapurpledress @maninapurpledr1]

@johnwelshtradez $magh How will this obvious pump & dump end? See below. $magh went public using a questionable underwriter named Bancroft. Look how much money investors have lost on Bancroft's other IPOs. PLS REPOST THIS LETS EXPOSE THEM @johnwelshtradez @StockJabber

[Utopia Capital Research @UtopiaCap]

Trying to understand what Alchemist AI $ALCH is actually supposed to do… 🤷‍♂️

After extensive testing, the web app doesn’t work at all — constant errors like “email rate limit exceeded” and “failed to start generation”. Support is completely silent, no responses anywhere.

I’ve attached screenshots so people can see what I’m seeing.

Is anyone able to explain what’s going on here? Because I’m not seeing any functional AI tech behind this product.
#AlchemistAI $ALCH #web3 #AI

[FuzzyPanda @FuzzyPandaShort]

NEW: We are short Eos Energy (EOSE), a zinc-based battery maker. We uncovered multiple gas leaks of deadly hydrogen bromide.

Worse, executives told us Eos falsified financials for DOE loan – we expect the DOE loan to be pulled and the debt to be immediately due.

[Adam Gefvert, CFA @Shiningboy]

If I was the management of $DTST, after selling their subsidiary today i would immediately announce a crypto treasury merger or say they are going to use their funds to buy crypto.

[Utopia Capital Research @UtopiaCap]

Totally fair point — and great eye on the Bosch/R. Bosch GmbH line.

We’re assuming those are the same core holding, just listed separately due to reporting structure or custodial differences. When you consolidate them, the math aligns with the ~54M outstanding shares.

In our case, we’ve intentionally grouped long-term aligned holders like Bosch, Lucerne, Mirabella, and ADSH as part of the "locked float." They’ve supported the company from the beginning and aren’t active sellers , more like strategic partners than traders.

ADR mechanics between the U.S. and Germany can add some reporting noise, but the float trap thesis still holds: You would be hard to find shares to short and the borrow rate 150% on IB for a reason.. nearly all shares are parked, with only a microscopic tradable float remaining.

Appreciate you digging in — if it all holds, this could be one of the most asymmetric float setups we’ve seen in a while.

[Utopia Capital Research @UtopiaCap]

🚨 $ADSE may be the tightest float trap on Nasdaq
✅ Insiders hold nearly 100%
❌ Naked shorts have no shares to cover
🔬 Microscopic public float
🔥 This setup could rival $GME
🎥 Full video breakdown here:

[White Diamond @WhiteResearch]

ZJK Industrial Is A Boring Nuts And Bolts Manufacturer – Evidence Suggests Their Claimed Collaboration With Nvidia Is A Lie

$ZJK

Read the full report here:

https://t.co/tyWWCF4d65